Monday, October 5, 2026

ESET Security Software Cuts CPU Usage 72% Through Intel AI Integration

ESET PROTECT reduced CPU utilization by 72% and background activity by 86% after integrating Intel Threat Detection Technology. The cybersecurity platform achieved Intel vPro Certified App status while maintaining detection efficacy through processor-level AI threat analysis.

LM Salvado

March 28, 2026

ESET Security Software Cuts CPU Usage 72% Through Intel AI Integration
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

ESET PROTECT reduced CPU utilization by 72% through integration with Intel Threat Detection Technology, demonstrating measurable efficiency gains from AI-powered security systems.1 The enterprise cybersecurity platform cut background activity by 86% and increased overall performance by 66% while maintaining threat detection rates.1

Intel TDT-DTECT applies artificial intelligence to processor-level execution patterns for threat detection, offloading security analysis from software to hardware.1 This approach enables real-time monitoring without the computational overhead of traditional endpoint security solutions that rely on signature-based scanning and behavioral analysis in software layers.

The collaboration between ESET and Intel resulted in vPro Certified App status for ESET PROTECT, validating the platform's integration with Intel's hardware-based security framework.1 Intel vPro certification requires applications to meet specific performance and compatibility standards across Intel's commercial processor ecosystem.

CPU utilization reductions of 60-85% represent significant cost savings for enterprises running security software across large device fleets.1 Lower processor loads translate to extended battery life on mobile devices, reduced cooling requirements in data centers, and improved responsiveness for business applications competing for system resources.

The enterprise security market is seeing increased integration between hardware manufacturers and software vendors. SentinelOne and Google Cloud announced a multi-year strategic collaboration for platform expansion on March 25, 2026, indicating broader industry movement toward integrated security architectures.1

Processor-level threat detection addresses a persistent challenge in enterprise IT: balancing security controls with user productivity. Traditional endpoint protection platforms can consume 15-30% of CPU resources during active scans, creating performance bottlenecks that lead to user frustration and policy circumvention.

The Intel TDT integration demonstrates how hardware-accelerated AI can solve software efficiency problems. By moving threat analysis to dedicated silicon, security vendors can maintain comprehensive monitoring without degrading system performance or requiring enterprises to provision more powerful hardware to accommodate security overhead.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com